EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications

Jorg Tost, Secil Ak-Aksoy, Daniele Campa, Chiara Corradi, Riccardo Farinella, Alejandro Ibáñez-Costa, Juan Dubrot, Julie Earl, Emma Barreto Melian, Agapi Kataki, Georgina Kolnikova, Gjorgji Madjarov und 8 weitere

Seminars in Cancer Biology · 2025

DOI: 10.1016/j.semcancer.2025.01.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2025. Verfasst von Jorg Tost und 19 weiteren Autor:innen. Beteiligte Einrichtung: Centre National de Recherche en Génomique Humaine, CEA - Institut de Biologie François Jacob, University Paris - Saclay, Evry, France. Electronic add…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Epigenesis, Genetic, Pancreatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 288 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Slovak Academy of Sciences, European Cooperation in Science and Technology, Slovak Research and Development Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by late detection and poor prognosis. Recent research highlights the pivotal role of epigenetic alterations in driving PDAC development and progression. These changes, in conjunction with genetic mutations, contribute to the intricate molecular landscape of the disease. Specific modifications in DNA methylation, histone marks, and non-coding RNAs are emerging as robust predictors of disease progression and patient survival, offering the potential for more precise prognostic tools compared to conventional clinical staging. Moreover, the detection of epigenetic alterations in blood and other non-invasive samples holds promise for earlier diagnosis and improved management of PDAC. This review comprehensively summarises current epigenetic research in PDAC and identifies persisting challenges. These include the complex nature of epigenetic profiles, tumour heterogeneity, limited access to early-stage samples, and the need for highly sensitive liquid biopsy technologies. Addressing these challenges requires the standardisation of methodologies, integration of multi-omics data, and leveraging advanced computational tools such as machine learning and artificial intelligence. While resource-intensive, these efforts are essential for unravelling the functional consequences of epigenetic changes and translating this knowledge into clinical applications. By overcoming these hurdles, epigenetic research has the potential to revolutionise the management of PDAC and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalEpigenesis, GeneticPancreatic NeoplasmsBiomarkers, TumorHumansDNA MethylationPrognosisGene Expression Regulation, NeoplasticEpigenomics

Stichwörter der Autor:innen

BiomarkerDNA methylationEpigenetic regulationNon-coding RNAPancreatic ductal adenocarcinoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Centre National de Recherche en Génomique Humaine, CEA - Institut de Biologie François Jacob, University Paris - Saclay, Evry, France. Electronic address: tost@cnrgh.fr.
  • Bursa Uludag University Faculty of Medicine, Medical Microbiology, Bursa 16059, Turkey. Electronic address: secilak@uludag.edu.tr.
  • Department of Biology, University of Pisa, via Derna 1, Pisa 56126, Italy. Electronic address: daniele.campa@unipi.it.
  • Department of Biology, University of Pisa, via Derna 1, Pisa 56126, Italy. Electronic address: chiara.corradi@phd.unipi.it.
  • Department of Biology, University of Pisa, via Derna 1, Pisa 56126, Italy. Electronic address: riccardo.farinella@phd.unipi.it.
  • Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Cell Biology, Physiology, and Immunology, University of Cordoba, Reina Sofia University Hospital, Edificio IMIBIC, Avenida Men´endez Pidal s/n,…

Förderung

  • Slovak Academy of Sciences
  • European Cooperation in Science and Technology
  • Slovak Research and Development Agency
  • Spanish Association Against Cancer Scientific Foundation

Zitieren

APA

Tost, J., Ak-Aksoy, S., Campa, D., Corradi, C., Farinella, R., Ibáñez-Costa, A., Dubrot, J., Earl, J., Melian, E. B., Kataki, A., Kolnikova, G., Madjarov, G., Chaushevska, M., Strnadel, J., Tanić, M., Tomas, M., Dubovan, P., Urbanova, M., Buocikova, V., & Smolkova, B. (2025). Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2025.01.003

Vancouver

Tost J, Ak-Aksoy S, Campa D, Corradi C, Farinella R, Ibáñez-Costa A, et al. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Seminars in Cancer Biology. 2025. doi:10.1016/j.semcancer.2025.01.003

BibTeX
@article{Tost2025,
  author = {Tost, Jorg and Ak-Aksoy, Secil and Campa, Daniele and Corradi, Chiara and Farinella, Riccardo and Ibáñez-Costa, Alejandro and Dubrot, Juan and Earl, Julie and Melian, Emma Barreto and Kataki, Agapi and Kolnikova, Georgina and Madjarov, Gjorgji and Chaushevska, Marija and Strnadel, Jan and Tanić, Miljana and Tomas, Miroslav and Dubovan, Peter and Urbanova, Maria and Buocikova, Verona and Smolkova, Bozena},
  title = {Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications},
  journal = {Seminars in Cancer Biology},
  year = {2025},
  doi = {10.1016/j.semcancer.2025.01.003}
}
Kostenlos starten →